Navigation Links
Alchem International Opens Sales and Marketing Office in the U.S.
Date:2/1/2012

MINNEAPOLIS, February 1, 2012 /PRNewswire/ --

Alchem International Ltd. opens its first North American office in Minneapolis. The sales and marketing office will be spearheaded by Laurent Leduc, former Vice President of Frutarom Health, Inc. This office will cater to the rapidly growing demand in North America for GMP manufacturers of extracts and their purified derivatives for the supplement, pharmaceutical and cosmetic industries.

Alchem International Ltd. is the largest manufacturer of extracts and their purified derivatives in India. Approved by the U.S. FDA, the company has three facilities that comply with international GMP standards. Alchem manufactures herbal extracts and pure pharmaceuticals that conform to USP and other international standards. Its ingredient offerings include natural extracts such as vinpocetine, Coleus Forskolin, sennosides and quinine. Alchem prides itself on its product quality, customer satisfaction and commitment to the environment.

Born in France, Leduc began his international career at Sandoz/Novartis in Minneapolis. In 1995, he led the creation of Acatris Health. Leduc's vast experience includes the release of innovative branded ingredients and proprietary blends.

"I'm very excited about opening Alchem's first North American office and welcome the opportunity to offer to the supplement and cosmetic industries premium quality ingredients and formulations supported by science," says Leduc. "My role will be to introduce the region to Alchem and its portfolio of high-quality ingredients, and to increase service to our customers in North America."

Adds Raman Mehta, CEO of Alchem International, "Our goal is to build long-term supplier relations with manufacturers that, like Alchem, are dedicated to quality and that share our passion to help consumers live a healthy life. Alchem is improving the bioavailability of well-known dietary supplement ingredients, such as silymarin and curcumin, via proprietary technology and is developing new proprietary topical blends for the cosmetics industry."

"We are already seeing an increased demand for our vinpocetine, a new ingredient launch in 2011," continues Leduc. "Vinpocetine is used as a drug for memory enhancement in many countries, and is sold as a dietary supplement in the U.S. Alchem's pharmaceutical-grade vinpocetine is naturally-derived, and is produced in our state-of-the-art facility inspected by the U.S. FDA with zero 493s. Further, it meets European Pharmacopoeia standards."

For further information, please contact:

Laurent Leduc, COO Alchem USA Inc., Tel: +1-952-933-3822, Cell: +1-612-802-6124, laurent@alcheminternational.com

http://www.alcheminternational.com


'/>"/>
SOURCE Alchem International Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. P Summit calls for a new alchemy around phosphorus and food
2. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
5. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
6. PAREXEL International to Present at J.P. Morgan Healthcare Conference
7. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
8. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
9. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
10. International Attendance for Networking and Education at Informex Beyond Manufacturing
11. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , Feb. ... regenerative medicine company, and Beyond Type 1, a not-for-profit ... 1 diabetes, today announced a grant from Beyond Type ... cure for type 1 and other insulin-requiring diabetes.  ... been developing innovative stem cell-derived cell replacement therapies with ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel , ... Research Systems, LLC (KRS) clinical development program. KRS is a neurotechnology spin-out ... research and clinical applications. The terms of the transaction were not disclosed. ...
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , ... from around the world, is pleased to announce the 2nd annual Precision Medicine ... This premier, online-only conference focused on the development and advancements in precision medicine. ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):